Crossmark

Safety and efficacy of direct Cardiac Shockwave Therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-020-04369-0

Published Online: 2020-05-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pölzl, Leo

Nägele, Felix

Graber, Michael

Hirsch, Jakob

Lobenwein, Daniela

Mitrovic, Martina

Mayr, Agnes

Theurl, Markus

Schreinlechner, Michael

Pamminger, Matthias

Dorfmüller, Christian

Grimm, Michael

Gollmann-Tepeköylü, Can

Holfeld, Johannes https://orcid.org/0000-0001-6623-0595
License Information

Text and Data Mining valid from 2020-05-30

Version of Record valid from 2020-05-30
More Information

Article History

Received: 27 September 2019

Accepted: 5 May 2020

First Online: 30 May 2020

Competing interests

: JH, CD and MG are shareholders of Heart Regeneration Technologies GmbH, an Innsbruck Medical University spin-off aiming to promote Cardiac Shockwave Therapy (). All other authors have nothing to disclose.

Document is current

Any future updates will be listed below